Picture this: your mother was diagnosed with Parkinson’s disease last year, and her neurologist started a standard medicine. At a family dinner, a relative hands her a bottle labeled as an NAD booster and mentions that research-catalog NAD+ is sold online too. The pitch is that NAD “recharges” the brain cells Parkinson’s damages. Should she add it?
The clearest answer so far comes from a large trial published this month. In NOPARK, a year of nicotinamide riboside, an oral supplement the body converts into NAD, did not improve Parkinson’s symptoms, and overall scores came out slightly worse than placebo.
Why researchers had real hope
The idea was not an internet invention. NAD is a molecule cells use to produce energy, and researchers in Norway asked whether raising it could protect brain cells in Parkinson’s. Their NADPARK study, published in Cell Metabolism in 2022, gave nicotinamide riboside or placebo to 30 newly diagnosed people for 30 days. Brain scans showed a significant but variable rise in brain NAD. People whose brain NAD rose showed shifts in brain metabolism linked to mild clinical improvement, and the team called for larger trials.
A 2023 follow-up called NR-SAFE tested a much higher amount in 20 people for four weeks. It was well tolerated and raised blood NAD up to fivefold. Rating-scale scores improved, but the authors noted that this was also tied to a shorter time since participants’ last levodopa dose, which muddies the picture. Both studies were small, short, and designed to check safety and biology rather than prove a benefit.
What the year-long NOPARK trial found
NOPARK, published in JAMA on October 8, 2026, was the real test. It was a double-blind, placebo-controlled phase 3 trial at 11 centers in Norway. It randomized 410 people with Parkinson’s diagnosed within the past two years, all at an early stage and on stable Parkinson’s medicine, to oral nicotinamide riboside or a matching placebo for 52 weeks.
The main measure was a standard Parkinson’s rating scale covering daily life and movement. Scores worsened by 2.45 points on nicotinamide riboside and improved by 0.27 points on placebo, a difference of 2.72 points favoring placebo. That gap is smaller than the 5.2-point worsening the authors list as clinically important, but it points the wrong way. Non-movement symptoms, measured on a separate scale that covers areas such as sleep, mood, and memory, also worsened more in the supplement group. Four of five key secondary measures showed no difference. Serious adverse events were less common with the supplement, 8.3 percent versus 14.1 percent on placebo.
The authors concluded that the findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson’s. Two of them hold patents on the approach licensed to Niagen Bioscience, a company that sells nicotinamide riboside, which makes a negative report from this team especially worth noting.
What it means for NAD+ products and the next neurology visit
NOPARK tested an oral precursor, not NAD+ injections, IV drips, or research-catalog NAD+. No trial shows those do better for Parkinson’s. The broader lesson is that raising NAD in blood or brain did not translate into people feeling or moving better, which is why a lab marker going up is not the same as a patient improving. A research-catalog NAD+ listing is sold as laboratory material, and nothing in these trials turns it into a Parkinson’s therapy.
Bring every supplement bottle to the appointment and mention the NOPARK trial by name. Do not stop or change prescribed Parkinson’s medicine without the neurologist. MedlinePlus notes that there is no cure for Parkinson’s, but that a variety of medicines sometimes help symptoms dramatically. Families who want to help research can ask whether a well-designed clinical trial is enrolling nearby.
Not medical advice.
Sources
- Brakedal B et al. Nicotinamide riboside for patients with early-stage Parkinson disease: the NOPARK randomized clinical trial. JAMA, 2026 (PubMed)
- ClinicalTrials.gov record NCT03568968 (NOPARK)
- Brakedal B et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease. Cell Metab, 2022 (PubMed)
- Berven H et al. NR-SAFE: randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. Nat Commun, 2023 (PubMed Central)
- MedlinePlus: Parkinson’s disease
Related reading
- Before booking an NAD+ IV drip: what the infusion studies recorded
- NAD precursors can raise blood markers without proving anti-aging
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-13 PT. Not medical advice.